Laurion Capital Management’s Sage Therapeutics SAGE Stock Holding History

Laurion Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,240	Closed	-$1.49M	–	879
2020 Q4	$1.49M	Buy	+17,240	New	+$1.27M	0.01%	368
2020 Q2	–	Sell	-33,800	Closed	-$971K	–	1146
2020 Q1	$971K	Buy	+33,800	New	+$1.96M	0.01%	488
2018 Q1	–	Sell	-35,052	Closed	-$5.77M	–	1643
2017 Q4	$5.77M	Buy	+35,052	New	+$3.4M	0.03%	476
2016 Q4	–	Sell	-32,300	Closed	-$1.49M	–	1263
2016 Q3	$1.49M	Buy	+32,300	New	+$1.31M	0.01%	523
2016 Q2	–	Sell	-9,500	Closed	-$305K	–	997
2016 Q1	$305K	Buy	+9,500	New	+$334K	﹤0.01%	589

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Laurion Capital Management's SAGE Position: Q1 2021 in Review

Laurion Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2021, closing a stake of 17,240 shares — an estimated $1.49M sold.

Laurion Capital Management first reported a position in SAGE in Q1 2016 and held it in 5 quarters. The position peaked at $5.77M in Q4 2017. 263 funds tracked by Wall St. Rank hold SAGE as of Q1 2021.

Laurion Capital Management reported no remaining Sage Therapeutics position as of Q1 2021 after selling out during the quarter.
Laurion Capital Management sold 17,240 Sage Therapeutics shares in Q1 2021, an estimated $1.49M.
Laurion Capital Management first reported a position in Sage Therapeutics in Q1 2016 and held it in 5 quarters.
Laurion Capital Management's Sage Therapeutics position peaked at $5.77M in Q4 2017.
263 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2021.

Based on Laurion Capital Management's 13F filing for Q1 2021, filed 14 May 2021.